In the Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15,which bears a shorter p190 isoform of oncogenic BCR-ABL1, 9 showed reduced activity with an IC50 value of 410 nM.Finally, to confirm that the antiproliferative activity is due tospecific targeting of BCR-ABL1, 9 was assessed in theleukemia cell line Molt-4, which is negative for BCR-ABL1, and thecompound exhibited a markedly decreased IC50 value of >2μM, as also seen with bosutinib. This evidence concerns the gene BCR and acute lymphoblastic leukemia.